In the biotech space, Dynavax Technologies DVAX soared more than 30% from its converged 50-day and 200-day moving averages following news it’s being acquired by Sanofi SNY. Sanofi will pay $2.2 billion in cash, or $15.50 per Dynavax share. Dynavax has vaccines for hepatitis B and a vaccine candidate for shingles.
Stock market today: Dow jumps, S&P 500 rises toward record; drug maker soars on FDA news (live coverage)
view original post